Etoh T, Inoue H, Tanaka S, Barnard G F, Kitano S, Mori M
Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan.
Cancer Res. 2001 Mar 1;61(5):2145-53.
Tumor angiogenesis progresses by a dynamic balance between tumor vascular regression and growth. Angiopoietin (Ang)-2 (the natural antagonist for the angiogenic Tie-2 receptor) and vascular endothelial growth factor (VEGF) are thought to be critical regulators in this process; therefore, these may play a critical role in cancer aggressiveness. The aim of this study was to clarify the clinical and biological significance of the expression of Ang-2 in human gastric cancers and to investigate the relationship between Ang-2 together with VEGF and the induction of proteases such as matrix metalloproteinases (MMPs) in the process of tumor development. Eighty-five individuals with gastric cancer, who had undergone surgery without preoperative treatment, were studied. A stable transfectant of the human MKN-7 gastric cancer cell lines with an Ang-2 expression vector was used for the experimental study. First, we examined the relationship between the mRNA expression of Angs by Northern blot analysis and clinicopathological features. High Ang-2-expression cases showed more frequent vascular involvement and more advanced stages of disease compared with low Ang-2-expression cases (P < 0.05). With regard to prognosis, the survival time for patients in the high-Ang-2 mRNA group was significantly shorter (P < 0.05). When we examined the localization of Ang-2 in human gastric cancers, immunohistochemical analysis revealed that this protein was expressed predominantly in cancer tissues when compared with normal tissues. Interestingly it was expressed not only in endothelia cells (ECs) but also in cancer cells. Second, Ang-2-transfected cells were implanted in vivo into the gastric walls of nude mice. Ang-2-transfectant mice developed highly metastatic tumors with hypervascularity as compared with MKN-7 or control vector-transfectant tumors. There was a significant correlation between Ang-2 mRNA expression and lower grade of vessel maturation. Third, on the basis of the in vivo data, we focused on production of proteases such as MMPs to investigate possible mechanisms in these processes. MMP-1, MMP-9, and urokinase-type plasminogen activator in ECs were strongly up-regulated by Ang-2 in the presence of VEGF in vitro. These data suggest that production of Ang-2 is implicated in tumor development in human gastric cancers. Its production may contribute to tumor angiogenesis by induction of proteases in ECs, which may be enhanced in the presence of VEGF.
肿瘤血管生成通过肿瘤血管消退与生长之间的动态平衡而进展。血管生成素(Ang)-2(血管生成性Tie-2受体的天然拮抗剂)和血管内皮生长因子(VEGF)被认为是这一过程中的关键调节因子;因此,它们可能在癌症侵袭性中发挥关键作用。本研究的目的是阐明Ang-2在人胃癌中表达的临床和生物学意义,并研究Ang-2与VEGF共同作用以及在肿瘤发展过程中诱导基质金属蛋白酶(MMPs)等蛋白酶之间的关系。对85例未经术前治疗即接受手术的胃癌患者进行了研究。用人MKN-7胃癌细胞系与Ang-2表达载体构建的稳定转染细胞用于实验研究。首先,我们通过Northern印迹分析检测了Angs的mRNA表达与临床病理特征之间的关系。与低Ang-2表达病例相比,高Ang-2表达病例血管受累更频繁,疾病分期更晚(P<0.05)。关于预后,高Ang-2 mRNA组患者的生存时间显著缩短(P<0.05)。当我们检测Ang-2在人胃癌中的定位时,免疫组织化学分析显示,与正常组织相比,该蛋白主要在癌组织中表达。有趣的是,它不仅在内皮细胞(ECs)中表达,也在癌细胞中表达。其次,将Ang-2转染细胞体内植入裸鼠胃壁。与MKN-7或对照载体转染肿瘤相比,Ang-2转染的小鼠形成了具有高度血管化的高转移性肿瘤。Ang-2 mRNA表达与血管成熟度较低之间存在显著相关性。第三,基于体内数据,我们聚焦于MMPs等蛋白酶的产生,以研究这些过程中的可能机制。在体外,在VEGF存在的情况下,Ang-2可强烈上调ECs中的MMP-1、MMP-9和尿激酶型纤溶酶原激活剂。这些数据表明,Ang-2的产生与人类胃癌的肿瘤发展有关。其产生可能通过诱导ECs中的蛋白酶促进肿瘤血管生成,在VEGF存在的情况下这种促进作用可能会增强。